All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Why do we see improved survival after allo-HSCT for young patients with AML?
Bookmark this article
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Ali Bazarbachi, American University of Beirut Medical Center, Beirut, LB, about allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with AML.
Why do we see improved survival after allo-HSCT for young patients with AML?
Currently, the most important cause of treatment failure is disease relapse after allo-HSCT. The prognosis for these patients has been very poor, however, recent changes in management have started to have an impact. Using data from the EBMT registry of more than 8,000 patients, Ali Bazarbachi's team asked what the influences of year of relapse and relapse characteristics were on outcomes after allo-HSCT.
Following on from this analysis, we asked, Why do we see improved survival after allo-HSCT for young patients with AML?
Your opinion matters
33 votes - 31 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox